

Lecture Title:

Enabling Epigenetic Drug Discovery Through Quality Proteins and Assay Services

Panelist:

Dr Ekaterina Kuznetsova (Reaction Biology, United States)



Ekaterina Kuznetsova, PhD joined Reaction Biology in 2014, concentrating on developing new assays for epigenetic targets, and leading Reaction Biology's protein production group. Dr. Kuznetsova has a broad background in enzymatic assay development and has intensive experience in working with epigenetic targets, as well as other enzymatic families. Dr. Kuznetsova's research is published in a number of peer-reviewed journals, including the Journal of Biological Chemistry, Nature Biotechnology, and ACS Medicinal Chemistry Letters.

She received her Ph.D. from the University of Toronto in 2009, focusing on areas of proteomics and biochemistry. She continued her training as a postdoctoral scientist at the Structural Genomics Consortium (MBB/Karolinska Institute, Sweden), working on the evaluation of PARP inhibitors. After that, Dr. Kuznetsova worked at SGC Toronto, University of Toronto as a Research Associate concentrating on epigenetic assay development and HTS for early-stage drug discovery.